BRISTOL-MYERS SQUIBB COMPANY (NYSE: BMY)

BRISTOL-MYERS SQUIBB COMPANY

NYSE: BMY (Bristol-Myers Squibb Company)

Last update: 21 Feb, 10:11AM

60.66

0.36 (0.60%)

Add to watchlist

Previous Close	60.30
Open	60.62
Volume	9,598,102
Avg. Volume (3M)	14,587,433
Market Cap	123,532,492,800

Price / Earnings (TTM)	17.53
Price / Earnings (Forward)	9.89
Price / Sales	2.58
Price / Book	6.74

52 Weeks Range	42.52 (-29%) — 63.33 (4%)
Earnings Date	30 Apr 2026
TTM Dividend Yield	4.84%

Market Trend

		Short Term	Medium Term
Industry	Drug Manufacturers - General (US)	Bullish	Mixed
	Drug Manufacturers - General (Global)	Bullish	Mixed
Stock	Bristol-Myers Squibb Company	Bullish	Bullish

AIStockmoo Score

1.5

Analyst Consensus	1.5
Insider Activity	-1.5
Price Volatility	-1.5
Technical Moving Averages	5.0
Technical Oscillators	4.0
Average	1.50

Similar Stocks

Stock	Market Cap	DY	P/E (TTM)	P/B
BMY	124 B	4.84%	17.53	6.74
JNJ	579 B	2.11%	21.81	7.25
ABBV	404 B	0.72%	97.33	50.46
MRK	306 B	0.65%	17.01	5.65
PFE	154 B	6.20%	19.89	1.75
GSK	123 B	1.62%	16.19	5.29

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Sector	Healthcare
Industry	Drug Manufacturers - General
Investment Style	Large Value
% Held by Insiders	0.07%
% Held by Institutions	82.11%

52 Weeks Range	42.52 (-29%) — 63.33 (4%)
Price Target Range	37.00 (-39%) — 75.00 (23%)
High	75.00 (Barclays, 23.64%)	Buy
	75.00 (Piper Sandler, 23.64%)	Buy
Median	61.00 (0.56%)
Low	37.00 (Morgan Stanley, -39.00%)	Sell
Average	62.64 (3.26%)
Total	6 Buy, 4 Hold, 1 Sell
Avg. Price @ Call	58.58

Firm	Date	Target Price	Call	Price @ Call
RBC Capital	25 Feb 2026	60.00 (-1.09%)	Hold	61.30
Piper Sandler	23 Feb 2026	75.00 (23.64%)	Buy	61.25
Piper Sandler	28 Jan 2026	66.00 (8.80%)	Buy	54.62
Barclays	20 Feb 2026	75.00 (23.64%)	Buy	60.66
Citigroup	06 Feb 2026	64.00 (5.51%)	Hold	61.99
Citigroup	27 Jan 2026	60.00 (-1.09%)	Hold	55.56
Guggenheim	06 Feb 2026	72.00 (18.69%)	Buy	61.99
Guggenheim	12 Dec 2025	62.00 (2.21%)	Buy	52.41
Wells Fargo	06 Feb 2026	60.00 (-1.09%)	Hold	61.99
Wells Fargo	10 Dec 2025	55.00 (-9.33%)	Hold	51.21
Leerink Partners	13 Jan 2026	60.00 (-1.09%)	Buy	55.92
Scotiabank	09 Jan 2026	60.00 (-1.09%)	Hold	55.86
UBS	07 Jan 2026	65.00 (7.15%)	Buy	56.72
B of A Securities	15 Dec 2025	61.00 (0.56%)	Buy	54.29
Morgan Stanley	12 Dec 2025	37.00 (-39.00%)	Sell	52.41
Show more

Name	Avg. Buy ($)	Avg. Sell ($)	Net Quantity	Net Value ($)
HICKEY BENJAMIN	-	62.37	-1,672	-104,283
Aggregate Net Quantity				-1,672
Aggregate Net Value ($)				-104,283
Aggregate Avg. Buy ($)				-
Aggregate Avg. Sell ($)				62.37

Name	Holder	Date	Type	Quantity	Price	Value ($)
HICKEY BENJAMIN	Officer	27 Feb 2026	Disposed (-)	1,672	62.37	104,283
HICKEY BENJAMIN	Officer	27 Feb 2026	Option execute	3,286	-	-

Date	Type	Details
20 Feb 2026	CNBC	With Trump's 'reciprocal' tariffs struck down, here are the industries still facing higher rates
05 Feb 2026	Announcement	Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025
04 Feb 2026	Announcement	Bristol Myers Squibb Teams Up with Kasey Keller to Share His Lymphoma Journey with Breyanzi
03 Feb 2026	Announcement	Bristol Myers Squibb Introduces "Change the Target. Change What’s Possible.” to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care
20 Jan 2026	Announcement	Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer
20 Jan 2026	CNBC	Drug pricing, patent losses and deals: Here's what pharma execs see ahead in the industry
12 Jan 2026	Announcement	Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
02 Jan 2026	Announcement	Bristol Myers Squibb to Present at J.P. Morgan’s 44th Annual Healthcare Conference
19 Dec 2025	Announcement	Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
19 Dec 2025	CNBC	Nine of the largest pharma companies ink deals with Trump to lower drug prices
18 Dec 2025	Announcement	Bristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026
11 Dec 2025	Announcement	U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma
10 Dec 2025	Announcement	Bristol Myers Squibb Announces Dividend Increase
08 Dec 2025	Announcement	Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025
Show more

TTM Dividend Yield	4.84%
5Y Average Dividend Yield	3.20%
Payout Ratio	91.04%

Ex Date	Announcement Date	Payment Date	Details
03 Jan 2025	11 Dec 2024	03 Feb 2025	0.62 Cash
04 Oct 2024	10 Sep 2024	01 Nov 2024	0.6 Cash
05 Jul 2024	18 Jun 2024	01 Aug 2024	0.6 Cash
04 Apr 2024	01 Mar 2024	01 May 2024	0.6 Cash
04 Jan 2024	06 Dec 2023	01 Feb 2024	0.6 Cash
05 Oct 2023	20 Sep 2023	01 Nov 2023	0.57 Cash
06 Jul 2023	14 Jun 2023	01 Aug 2023	0.57 Cash
06 Apr 2023	03 Mar 2023	01 May 2023	0.57 Cash
05 Jan 2023	08 Dec 2022	01 Feb 2023	0.57 Cash
06 Oct 2022	14 Sep 2022	01 Nov 2022	0.54 Cash
30 Jun 2022	15 Jun 2022	01 Aug 2022	0.54 Cash
31 Mar 2022	01 Mar 2022	02 May 2022	0.54 Cash
06 Jan 2022	13 Dec 2021	01 Feb 2022	0.54 Cash
30 Sep 2021	09 Sep 2021	01 Nov 2021	0.49 Cash
01 Jul 2021	17 Jun 2021	02 Aug 2021	0.49 Cash
31 Mar 2021	01 Mar 2021	03 May 2021	0.49 Cash
31 Dec 2020	10 Dec 2020	01 Feb 2021	0.49 Cash
01 Oct 2020	10 Sep 2020	02 Nov 2020	0.45 Cash
02 Jul 2020	11 Jun 2020	03 Aug 2020	0.45 Cash
02 Apr 2020	02 Mar 2020	01 May 2020	0.45 Cash
02 Jan 2020	06 Dec 2019	03 Feb 2020	0.45 Cash
03 Oct 2019	12 Sep 2019	01 Nov 2019	0.41 Cash
03 Jul 2019	14 Jun 2019	01 Aug 2019	0.41 Cash
04 Apr 2019	08 Mar 2019	01 May 2019	0.41 Cash
03 Jan 2019	07 Dec 2018	01 Feb 2019	0.41 Cash
04 Oct 2018	13 Sep 2018	01 Nov 2018	0.4 Cash
05 Jul 2018	15 Jun 2018	01 Aug 2018	0.4 Cash
05 Apr 2018	01 Mar 2018	01 May 2018	0.4 Cash
04 Jan 2018	07 Dec 2017	01 Feb 2018	0.4 Cash
05 Oct 2017	13 Sep 2017	01 Nov 2017	0.39 Cash
05 Jul 2017	13 Jun 2017	01 Aug 2017	0.39 Cash
05 Apr 2017	02 Mar 2017	01 May 2017	0.39 Cash
04 Jan 2017	08 Dec 2016	01 Feb 2017	0.39 Cash
05 Oct 2016	03 Aug 2016	01 Nov 2016	0.38 Cash
29 Jun 2016	07 Jun 2016	01 Aug 2016	0.38 Cash
30 Mar 2016	03 Mar 2016	02 May 2016	0.38 Cash
30 Dec 2015	08 Dec 2015	01 Feb 2016	0.38 Cash
30 Sep 2015	17 Sep 2015	02 Nov 2015	0.37 Cash
01 Jul 2015	16 Jun 2015	03 Aug 2015	0.37 Cash
01 Apr 2015	02 Mar 2015	01 May 2015	0.37 Cash
30 Dec 2014	09 Dec 2014	02 Feb 2015	0.37 Cash
01 Oct 2014	16 Sep 2014	03 Nov 2014	0.36 Cash
01 Jul 2014	17 Jun 2014	01 Aug 2014	0.36 Cash
02 Apr 2014	03 Mar 2014	01 May 2014	0.36 Cash
31 Dec 2013	19 Dec 2013	03 Feb 2014	0.36 Cash
02 Oct 2013	17 Sep 2013	01 Nov 2013	0.35 Cash
02 Jul 2013	19 Jun 2013	01 Aug 2013	0.35 Cash
Show more

Annual Dividend Yield

Year	Annual Dividend ($)	Frequency/Year	Yield %
2025	0.620	1	1.15
2024	2.40	4	4.24
2023	2.28	4	4.44
2022	2.16	4	3.00
2021	1.96	4	3.14
2020	1.80	4	2.90
2019	1.64	4	2.56
2018	1.60	4	3.08
2017	1.56	4	2.55
2016	1.52	4	2.60
2015	1.48	4	2.15
2014	1.44	4	2.44
2013	0.700	2	1.32
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Realized Profit	-
Unrealized Profit	-
Dividend Received 2026	-
Total Profit	-
Avg. Return	-
Quantity (Buy)	-
Avg. Price (Buy)	-
Quantity (Sold)	-
Avg. Price (Sold)	-

No stocks matching your criteria

Profit Margin	11.38%
Operating Margin (TTM)	31.57%
Diluted EPS (TTM)	2.68
Quarterly Revenue Growth (YOY)	-5.60%
Quarterly Earnings Growth (YOY)	-95.90%

Total Debt/Equity (MRQ)	293.85%
Current Ratio (MRQ)	1.28
Operating Cash Flow (TTM)	14.31 B
Levered Free Cash Flow (TTM)	13.93 B

Return on Assets (TTM)	7.24%
Return on Equity (TTM)	31.99%

Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)